Evidence map›Paper›PMID 37314541›Full record

ArticleAnnals of surgical oncology2023

Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous Neoplasms (Pseudomyxoma Peritonei).

Abigail I Wald, James F Pingpank, Melanie Ongchin, Lauren B Hall, Heather Jones, Shannon Altpeter, Michelle Liebdzinski, Ahmed B Hamed, Joshua Derby, Marina N Nikiforova and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. High prevalence ofPleura and peritoneum · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Abigail I WaldDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
James F PingpankDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Melanie OngchinDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Lauren B HallDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Heather JonesDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Shannon AltpeterDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Michelle LiebdzinskiDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ahmed B HamedDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Joshua DerbyDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Marina N NikiforovaDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Phoenix D BellDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Alessandro PanicciaDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Amer H ZureikatDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Vikram C GorantlaDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
John C RheeDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Roby ThomasDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
David L BartlettAHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Katelyn SmithDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Patrick HennDepartment of Pathology, University of Colorado Hospital, Aurora, CO, USA.
Brian K TheisenDepartment of Pathology, Henry Ford Health System, Detroit, MI, USA.
Susan ShyuDepartment of Pathology, WellSpan York Hospital, York, PA, USA.
Akram ShalabyDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
M Haroon A ChoudryDepartment of Surgery, UPMC Cancer Pavilion, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. choudrymh@upmc.edu.
Aatur D SinghiDepartment of Pathology, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. singhiad@upmc.edu.ORCID http://orcid.org/0000-0003-3930-7096
University of Pittsburgh Medical Center · USPresbyterian Hospital · USAllegheny Health Network · USHenry Ford Health System · USUniversity of Colorado Hospital · USUPMC Health System · USWellSpan York Hospital · US

Funding

Validation of biomarkers for risk prediction and early diagnosis of Pancreatic AdenocarcinomaU01CA200466 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Surinder K. Batra, Randall Brand · 2016 to 2026
$11.3M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Gavin E Arteel · 2019 to 2026
$10.9M
NCI NIH HHS 1U01CA200466NIDDK NIH HHS P30DK120531
6 · The paper itself

Abstract

backgroundAppendiceal mucinous neoplasms (AMNs) with disseminated disease (pseudomyxoma peritonei) are heterogeneous tumors with variable clinicopathologic behavior. Despite the development of prognostic systems, objective biomarkers are needed to stratify patients. With the advent of next-generation sequencing (NGS), it remains unclear if molecular testing can improve the evaluation of disseminated AMN patients.

methodsTargeted NGS was performed for 183 patients and correlated with clinicopathologic features to include American Joint Committee on Cancer/World Health Organization (AJCC/WHO) histologic grade, peritoneal cancer index (PCI), completeness of cytoreduction (CC) score, and overall survival (OS).

resultsGenomic alterations were identified for 179 (98%) disseminated AMNs. Excluding mitogen-activated protein kinase genes and GNAS due to their ubiquitous nature, collective genomic alterations in TP53, SMAD4, CDKN2A, and the mTOR genes were associated with older mean age, higher AJCC/WHO histologic grade, lymphovascular invasion, perineural invasion, regional lymph node metastasis, and lower mean PCI (p < 0.040). Patients harboring TP53, SMAD4, ATM, CDKN2A, and/or mTOR gene alterations were found to have lower OS rates of 55% at 5 years and 14% at 10 years, compared with 88% at 5 years and 88% at 10 years for patients without the aforementioned alterations (p < 0.001). Based on univariate and multivariate analyses, genomic alterations in TP53, SMAD4, ATM, CDKN2A, and/or the mTOR genes in disseminated AMNs were a negative prognostic factor for OS and independent of AJCC/WHO histologic grade, PCI, CC score, and hyperthermic intraperitoneal chemotherapy treatment (p = 0.006).

conclusionsTargeted NGS improves the prognostic assessment of patients with disseminated AMNs and identifies patients who may require increased surveillance and/or aggressive management.

Indexed as

Adenocarcinoma, MucinousAppendiceal NeoplasmsPeritoneal NeoplasmsPseudomyxoma PeritoneiCytoreduction Surgical ProceduresHigh-Throughput Nucleotide SequencingHumansTOR Serine-Threonine KinasesTOR Serine-Threonine KinasesAppendixLAMNMucinous adenocarcinomaPseudomyxomaSignet ring cell carcinoma

Identifiers

PMID37314541
OpenAlexW4380577304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.